This study aims to construct a structuralized follow-up model for survivors of childhood hematological malignancies in China. Using a multicenter prospective cohort design, it will identify the burden and risk factors of late effects. The study hypothesizes that a standardized follow-up path managed by an electronic platform will improve follow-up compliance and reduce the missed diagnosis rate of late effects.
Diagnosed with childhood hematological malignancies (ALL, AML, Lymphoma, etc.), Completed primary treatment for ≥12 months.
Age 1-21 years.
Capable of completing follow-up and data collection.
Informed consent signed.
Severe organ failure preventing follow-up.
Major genetic or systemic diseases affecting growth/organ function.
Expected poor compliance or refusal to participate.
The Children's Hospital of Zhejiang University School of Medicine
Lead sponsor
Ningbo Women & Children's Hospital
Collaborator
Hangzhou Children's Hospital
Collaborator